{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:19Z","timestamp":1790874739673,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015391","name":"Myositis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>We aim to describe the immunoassays that have been  used for myositis autoantibody discovery with a focus on newer methods.  We describe recently identified myositis autoantibodies that do not yet form  part of routine clinical testing, highlighting what is known about their  associated clinical phenotype and potential clues as to their presence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Novel approaches to autoantibody detection have been  employed in recent years including chemiluminescent immunoassay,  phage immunoprecipitation-sequencing and modifications to the more  traditional immunoprecipitation technique. This has led to the discovery of  novel autoantibodies, including novel anti-aminoacyl-tRNA synthetase  autoantibodies and autoantibodies which modify cancer risk for patients  with anti-TIF1\u0263 associated dermatomyositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>New approaches to novel autoantibody detection have  facilitated autoantibody discovery and will enable the identification of  autoantibodies to a broader range of autoantigens. Challenges remain in  translating this knowledge into accessible testing particularly given the  rarity of most recently discovered autoantibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-024-01171-8","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:07:14Z","timestamp":1733371634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Newer Autoantibodies and Laboratory Assessments in Myositis"],"prefix":"10.1007","volume":"27","author":[{"given":"Georgina R","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"MacFadyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Tansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"1171_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019.","journal-title":"J Autoimmun"},{"key":"1171_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017;84:55\u201364.","journal-title":"J Autoimmun"},{"issue":"4","key":"1171_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. 2013;92(4):223\u201343.","journal-title":"Medicine"},{"issue":"1","key":"1171_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","volume":"22","author":"SL Tansley","year":"2020","unstructured":"Tansley SL, Snowball J, Pauling JD, Lissina A, Kuwana M, Rider LG, et al. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Res Therapy. 2020;22(1):117.","journal-title":"Arthritis Res Therapy"},{"issue":"12","key":"1171_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","volume":"19","author":"AGS Oldroyd","year":"2023","unstructured":"Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative. Nat Rev Rheumatol. 2023;19(12):805\u201317.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm-21-475","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zheng Y, Hao H, Yuan Y. Narrative review of autoantibodies in idiopathic inflammatory myopathies. Ann Transl Med. 2023;11(7):291.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1171_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2169\/internalmedicine.7824-21","volume":"61","author":"K Shinoda","year":"2022","unstructured":"Shinoda K, Okumura M, Yamaguchi S, Matsui A, Tsuda R, Hounoki H, et al. A comparison of line blots, enzyme-linked immunosorbent, and RNA-immunoprecipitation assays of antisynthetase antibodies in serum samples from 44 patients. Intern Med. 2022;61(3):313\u201322.","journal-title":"Intern Med"},{"issue":"6","key":"1171_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/BOR.0000000000000957","volume":"35","author":"MY Choi","year":"2023","unstructured":"Choi MY, Satoh M, Fritzler MJ. Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies. Curr Opin Rheumatol. 2023;35(6):383\u201394.","journal-title":"Curr Opin Rheumatol"},{"key":"1171_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/diagnostics13193080","volume":"13","author":"A Ghirardello","year":"2023","unstructured":"Ghirardello A, Gatto M, Franco C, Zanatta E, Padoan R, Ienna L, et al. Detection of Myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies. Diagnostics. 2023;13:19.","journal-title":"Diagnostics"},{"key":"1171_CR10","doi-asserted-by":"publisher","first-page":"102951","DOI":"10.1016\/j.jaut.2022.102951","volume":"134","author":"C Preger","year":"2023","unstructured":"Preger C, Notarnicola A, Hellstr\u00f6m C, Wigren E, Fernandes-Cerqueira C, Kvarnstr\u00f6m M, et al. Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies. J Autoimmun. 2023;134:102951.","journal-title":"J Autoimmun"},{"key":"1171_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/diagnostics13182929","volume":"13","author":"Y Norimatsu","year":"2023","unstructured":"Norimatsu Y, Matsuda KM, Yamaguchi K, Ono C, Okumura T, Kogo E, et al. The autoantibody array assay: a novel autoantibody detection method. Diagnostics. 2023;13:18.","journal-title":"Diagnostics"},{"key":"1171_CR12","doi-asserted-by":"publisher","first-page":"1255540","DOI":"10.3389\/fimmu.2023.1255540","volume":"14","author":"A Kuzumi","year":"2023","unstructured":"Kuzumi A, Norimatsu Y, Matsuda KM, Ono C, Okumura T, Kogo E, et al. Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array. Front Immunol. 2023;14:1255540.","journal-title":"Front Immunol"},{"issue":"5","key":"1171_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.5858\/arpa.2022-0331-OA","volume":"148","author":"Z Su","year":"2024","unstructured":"Su Z, Wang L, Gao X, Huang Z, Hu J, Yang B. Clinical performance of the line immunoassay, digital liquid chip method, and chemiluminescent immunoassay for detecting specific antinuclear antibodies. Arch Pathol Lab Med. 2024;148(5):566\u201372.","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"1171_CR14","first-page":"1048","volume":"37","author":"DF Fiorentino","year":"2019","unstructured":"Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L. Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clin Exp Rheumatol. 2019;37(6):1048\u201351.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"1171_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/1756-185X.14174","volume":"24","author":"TJ Beaton","year":"2021","unstructured":"Beaton TJ, Gillis D, Prain K, Morwood K, Anderson J, Goddard J, et al. Performance of myositis-specific antibodies detected on myositis line immunoassay to diagnose and sub-classify patients with suspected idiopathic inflammatory myopathy, a retrospective records-based review. Int J Rheum Dis. 2021;24(9):1167\u201375.","journal-title":"Int J Rheum Dis"},{"key":"1171_CR16","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.jtauto.2019.100013","volume":"2","author":"ACM Platteel","year":"2019","unstructured":"Platteel ACM, Wevers BA, Lim J, Bakker JA, Bontkes HJ, Curvers J, et al. Frequencies and clinical associations of myositis-related antibodies in the Netherlands: a one-year survey of all Dutch patients. J Transl Autoimmun. 2019;2:100013.","journal-title":"J Transl Autoimmun"},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"804037","DOI":"10.3389\/fimmu.2022.804037","volume":"13","author":"B Mulhearn","year":"2022","unstructured":"Mulhearn B, Li D, McMorrow F, Lu H, McHugh NJ, Tansley SL. A commercial Anti-TIF1\u03b3 ELISA is Superior to line and dot blot and should be considered as part of routine myositis-specific antibody testing. Front Immunol. 2022;13:804037.","journal-title":"Front Immunol"},{"issue":"8","key":"1171_CR18","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","volume":"59","author":"SL Tansley","year":"2020","unstructured":"Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology. 2020.","journal-title":"Rheumatology"},{"issue":"4","key":"1171_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","volume":"48","author":"C Bundell","year":"2016","unstructured":"Bundell C, Rojana-Udomsart A, Mastaglia F, Hollingsworth P, McLean-Tooke A. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology. 2016;48(4):363\u20136.","journal-title":"Pathology"},{"issue":"2","key":"1171_CR20","doi-asserted-by":"publisher","first-page":"101767","DOI":"10.1016\/j.berh.2022.101767","volume":"36","author":"AS Galindo-Feria","year":"2022","unstructured":"Galindo-Feria AS, Wang G, Lundberg IE. Autoantibodies: pathogenic or epiphenomenon. Best Pract Res Clin Rheumatol. 2022;36(2):101767.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1171_CR21","doi-asserted-by":"crossref","unstructured":"Pluk H, van BJA Hoeve, van SHJ Dooren, J Stammen-Vogelzangs et al. Autoantibodies to cytosolic 5\u2019-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397\u2013407.","DOI":"10.1002\/ana.23822"},{"issue":"4","key":"1171_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/ard-2022-222686","volume":"82","author":"J-B Vulsteke","year":"2023","unstructured":"Vulsteke J-B, Derua R, Dubucquoi S, Coutant F, Sanges S, Goncalves D, et al. Mass spectrometry-based identification of new anti-ly and known antisynthetase autoantibodies. Ann Rheum Dis. 2023;82(4):546\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1171_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/ard-2022-222441","volume":"82","author":"Y Hosono","year":"2023","unstructured":"Hosono Y, Sie B, Pinal-Fernandez I, Pak K, Mecoli CA, Casal-Dominguez M, et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies. Ann Rheum Dis. 2023;82(2):246\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1171_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","volume":"18","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Vulsteke JB, Tseng CW, Platteel ACM, Piette Y, Shovman O, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun rev. 2019;18(3):293\u2013305.","journal-title":"Autoimmun rev"},{"issue":"7","key":"1171_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879\u201389.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1171_CR26","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1093\/rheumatology\/keae245","volume":"63","author":"K Yoshida","year":"2024","unstructured":"Yoshida K, Takahashi S, Kawai R, Saito T, Hatachi S, Shintani A, et al. Combination of cytoplasmic and nuclear patterns on Hep-2 antinuclear antibody is useful as a screening test for anti-synthetase syndrome. Rheumatology. 2024;63(9):2590\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/keae245.","journal-title":"Rheumatology"},{"issue":"2","key":"1171_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.55563\/clinexprheumatol\/8xj0b9","volume":"40","author":"G Zanframundo","year":"2022","unstructured":"Zanframundo G, Faghihi-Kashani S, Scir\u00e8 CA, Bonella F, Corte TJ, Doyle TJ, et al. Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol. 2022;40(2):309\u201319.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1171_CR28","first-page":"277","volume":"42","author":"A Loganathan","year":"2024","unstructured":"Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, et al. Agreement between local and central anti-synthetase antibodies detection: results from the classification criteria of anti-synthetase syndrome project biobank. Clin Exp Rheumatol. 2024;42(2):277\u201387.","journal-title":"Clin Exp Rheumatol."},{"issue":"6","key":"1171_CR29","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1172\/JCI116493","volume":"91","author":"IN Targoff","year":"1993","unstructured":"Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Investig. 1993;91(6):2556\u201364.","journal-title":"J Clin Investig"},{"issue":"1","key":"1171_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/diagnostics13010156","volume":"13","author":"MJ Fritzler","year":"2023","unstructured":"Fritzler MJ, Bentow C, Satoh M, McHugh N, Ghirardello A, Mahler M. Deciphering the autoantibody response to the OJ antigenic complex. Diagnostics. 2023;13(1).","journal-title":"Diagnostics"},{"issue":"5","key":"1171_CR31","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1093\/rheumatology\/keac569","volume":"62","author":"T Sasai","year":"2023","unstructured":"Sasai T, Nakashima R, Shirakashi M, Hiwa R, Tsuji H, Kitagori K, et al. A new autoantibody to valyl transfer RNA synthetase associated with anti-synthetase syndrome. Rheumatology. 2023;62(5):e155\u20137.","journal-title":"Rheumatology"},{"issue":"7","key":"1171_CR32","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","volume":"60","author":"J Loarce-Martos","year":"2021","unstructured":"Loarce-Martos J, Lilleker JB, Parker M, McHugh N, Chinoy H. Polymyositis: is there anything left? a retrospective diagnostic review from a tertiary myositis centre. Rheumatology. 2021;60(7):3398\u2013403.","journal-title":"Rheumatology"},{"issue":"5","key":"1171_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/rheumatology\/kez406","volume":"59","author":"Z Betteridge","year":"2020","unstructured":"Betteridge Z, Chinoy H, Vencovsky J, Winer J, Putchakayala K, Ho P, et al. Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology. 2020;59(5):1026\u201330.","journal-title":"Rheumatology"},{"issue":"4","key":"1171_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Sen\u00e9cal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine. 2005;84(4):231\u201349.","journal-title":"Medicine"},{"issue":"2","key":"1171_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3899\/jrheum.221067","volume":"50","author":"NJ McHugh","year":"2023","unstructured":"McHugh NJ. Ro52, Myositis, and interstitial lung disease. J Rhuematol. 2023;50(2):161\u20133.","journal-title":"J Rhuematol"},{"issue":"2","key":"1171_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","volume":"64","author":"E Trallero-Aragu\u00e1s","year":"2012","unstructured":"Trallero-Aragu\u00e1s E, Rodrigo-Pend\u00e1s J, Selva-O\u2019Callaghan A, Mart\u00ednez-G\u00f3mez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523\u201332.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1171_CR37","doi-asserted-by":"publisher","first-page":"e150201","DOI":"10.1172\/JCI150201","volume":"132","author":"DF Fiorentino","year":"2022","unstructured":"Fiorentino DF, Mecoli CA, Rosen MC, Chung LS, Christopher-Stine L, Rosen A, et al. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. J Clin Investig. 2022;132(2).","journal-title":"J Clin Investig"},{"issue":"7","key":"1171_CR38","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/art.42474","volume":"75","author":"D Fiorentino","year":"2023","unstructured":"Fiorentino D, Mecoli CA, Igusa T, Albayda J, Paik JJ, Tiniakou E, et al. Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis. Arthritis Rheumatol. 2023;75(7):1238\u201345.","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-024-01171-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:02:28Z","timestamp":1770750148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-024-01171-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s11926-024-01171-8","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"17 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5"}}